IPH — Innate Pharma SA Share News
0.000.00%
Last trade - 00:00- €121.51m
- €130.82m
- €2.79m
Brief: Innate Pharma To Present New Lacutamab Data From TELLOMAK Trial
Brief: Innate Pharma Q1 Revenues Down At EUR 4.5 Mln
Brief: Innate Pharma FY Net Loss Widens To EUR 64 Million
Brief: Innate Pharma Advances Lacutamad Clinical Development Program
Brief: Innate Pharma SA Files For Stock Shelf Of Up To $200 Million
Brief: Innate's First NK Cell Engager Selected By Sanofi As Drug Candidate For Development
Innate Pharma: Dropped cancer treatment sinks shares
Brief: Innate Pharma To Return US And EU Lumoxiti Commercialisation Rights To AstraZeneca
French and Benelux stocks-Factors to watch on Friday
Brief: Innate Pharma To Present Additional Efficacy Data For Monalizumab In Combination With Cetuximab
Brief: Innate Pharma Nine-Months Revenue Down At 33.6 Million Euros
Innate Pharma: Jumps on EMA boost for experimental blood cancer drug
Brief: Innate Pharma Receives EMA PRIME Designation For Lacutamab In Sezary Syndrome
Brief: Innate Pharma: First Patient Dosed In Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
Innate Pharma: Attractive entry point, Kepler ups to buy
Brief: Innate Pharma H1 Net Result Turns To Loss Of EUR 10.3 Mln
Brief: Innate Pharma Gets Eur 6.8 Mln In Public Funding For COVID-19 Research
Brief: Innate Pharma Publishes EXPLORE COVID-19 Translational Study Findings
Brief: Innate Pharma Appoints Joyson Karakunnel Chief Medical Officer